

Human Papillomavirus (HPV) Vaccines: 13 Years Later

Vacinas contra o Papilomavírus Humano (HPV): 13 anos depois

Mauro Romero Leal Passos¹ 

WHAT BRINGS ME HERE?

The year was 2012, and two HPV vaccines — the bivalent (types 16 and 18) and the quadrivalent (types 6, 11, 16, and 18; HPV4v) — were commercially launched in Brazil. Both manufacturers focused their campaigns almost exclusively on cervical cancer prevention.

As a venereologist, he was one of the founders, in 1988, of the Brazilian Society of Sexually Transmitted Diseases and the STD Sector of the Federal Fluminense University — and, in 1989, of the Brazilian Journal of Sexually Transmitted Diseases — I had anogenital condylomata (warts) in men, women, and adolescents at the center of my daily practice. Gonorrhea, trichomoniasis, herpes, and syphilis were equally common.

Trained in gynecology at the Gynecology Institute of the Universidade Federal do Rio de Janeiro — founded by Professor Arnaldo de Moraes — I still recall the radical hysterectomy (Wertheim-Meigs surgery) for cervical cancer and the radical vulvectomy for vulvar cancer, vivid in my clinical memory (emotional scars?). It was natural, then, to engage fully in promoting, raising awareness of, and prescribing the HPV4v vaccine.

Individual prescription, however, was not enough. The public health impact required incorporation into the Unified Health System (SUS) — free and universally accessible.

Aware of the historic “Vaccine Revolt” that took place in Rio de Janeiro on November 10, 1904 — a popular uprising against compulsory smallpox vaccination⁽¹⁾ — I organized, along with many partners, a countermovement: the “Vaccine March.” Held on Copacabana Beach on Sunday, May 19, 2013, the March drew national and international attention, with coverage by the Oswaldo Cruz Foundation (Fiocruz),⁽²⁾ the *Correio Brasileiro*,⁽³⁾ and a 26-minute live interview with journalist Ricardo Boechat on Rádio Band News FM.⁽⁴⁾ The initiative was also featured in *HPV Today News* and on Brazilian civil-society platforms.^(5,6)

The most consequential development, however, was in health policy: in November 2013, the National Immunization Program of Brazil’s Ministry of Health (PNI-MS) incorporated the HPV4v vaccine into the public immunization schedule.⁽⁷⁾ For Brazilian public health, that was our victory — our “Oscar,” our World Cup.

Initially, vaccination was offered only to girls aged 11 to 13 years, in line with the cervical-cancer-prevention framing. Over time, and in response to accumulating scientific evidence, the PNI-MS gradually expanded eligibility to other population groups — a welcome, if incomplete, evolution.

WHERE DO WE STAND TODAY?

Figure 1⁽⁸⁾ and Table 1 summarize who is currently eligible for HPV vaccination through the SUS, as of May 2026.

WHY THIS MATTERS — AND WHAT REMAINS UNRESOLVED

The data in Table 1 reveal a critical inconsistency. For people living with HIV, on PrEP, or treated for cancer or a solid organ transplant, the SUS offers HPV4v only up to age 45. Yet for individuals with recurrent respiratory papillomatosis, high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, or victims of sexual violence, there is no age limit. A 46-year-old in these latter categories can be vaccinated; a 46-year-old living with HIV, or those using PrEP, cannot. Is there a scientific justification for this asymmetry?.


Two recent studies, published in indexed, peer-reviewed journals and based on Brazilian research subjects, reinforce the urgency of reform.

Beltrame et al.⁽⁹⁾ analyzed HPV genotypes in oral specimens from 700 men living with HIV in Mexico, Brazil, and Puerto Rico, finding an HPV prevalence of 27.9%, of which 11% were high-risk. The types covered by HPV4v and HPV9v were detected in 4.9% and 8.9% of participants, respectively — that is, nearly twice as many men carried high-risk oncogenic types not included in HPV4v. Of the participants, 197 (28.1%) were between 41 and 50 years old, suggesting that a substantial share was above the SUS’s current eligibility limit, May 2026.

Gomes et al.⁽¹⁰⁾ — including researchers from Brazil’s Ministry of Health — analyzed vaginal HPV in Brazilian cisgender women living with HIV and found an HPV prevalence of 72%, with 31% of HPV-positive cases occurring in women aged 46 or older. Moreover, 49.3% of the genotypes detected were not covered by HPV4v. These figures confirm that the current age limit leaves a broad, identifiable high-risk population unprotected.

Beyond the biostatistics, there is a health-equity dimension that appears in no spreadsheet or protocol. How does a person of 46, 47, 48, 49, 50 years or older — living with HIV, with cancer, or a solid-organ transplant recipient, sexually active — feel on hearing from her physician that the Ministry of Health does not authorize her HPV vaccination because the schedule permits it only up to age 45? And how does someone feel who has a high-risk oncogenic HPV — until proven otherwise, the first step toward malignancy — detected at screening, and who still cannot be vaccinated because no high-grade lesion has yet been established? These emotional burdens exist; they generate chronic stress and, in many cases, leave deep marks that will never be erased. They are health outcomes as real as the numbers — and, like them, preventable.

¹Physician, Full Professor, Head of the Sexually Transmitted Diseases Sector (Department of Microbiology and Parasitology, Biomedical Institute), Universidade Federal Fluminense, Niterói, RJ, Brazil.



Source: @hpvsemtabu

Figure 1. HPV vaccination schedules – updated 2024–2026.

The dimension of waste also deserves attention: HPV4v doses are regularly discarded at Brazilian health centers, expiring before use. A vaccine thrown away because of age-based eligibility restrictions, while high-risk individuals above the limit remain unprotected, represents a failure that is at once ethical and one of efficiency.

WHAT WE ARE CALLING FOR

We call for equality, equity, and effectiveness (complementing effectiveness and efficiency) in access to HPV vaccination through the SUS, specifically requesting the elimination of the upper age limit for the three-dose schedule in the following groups:

- People of both biological sexes living with HIV, on PrEP, undergoing cancer treatment, or who have received a solid-organ transplant;
- People of both biological sexes with high-risk HPV detected at any anatomical site (cervix, vulva, vagina, anus, penis, oral cavity);
- People of both biological sexes with a cytological diagnosis of ASCUS (Squamous cell alteration of undetermined significance) or ASC-H (Squamous cell alteration not excluding high-grade lesion);
- People of both biological sexes with condyloma acuminatum at any anatomical site, regardless of age.
- People of both biological sexes who are sex workers.

THE CASE FOR REPLACING HPV4V WITH HPV9V IN THE SUS

The two studies cited^(9,10) also support the need for an immediate transition, within the SUS, from HPV4v (types 6, 11, 16, and 18) to HPV9v (types 6, 11, 16, 18, 31, 33, 45, 52, and 58). HPV9v more than doubles the coverage of high-risk oncogenic types, directly reducing the burden of HPV-attributable neoplasms. The barrier to this transition is political, not financial: treating HPV-related cancers — including radical surgery, prolonged hospitalization, and palliative care — costs the Brazilian health system far more than reformulating vaccine procurement. One further argument is decisive: HPV4v is no longer available on the Brazilian private market; anyone seeking broader coverage must purchase HPV9v at their own expense. The current scenario thus creates a two-tier system: those who can afford it are better protected than those who depend, only, on the SUS.

The path to the necessary adjustments requires, first, a political decision — by health managers, scientific societies, and civil

society — to demand these changes; and then, should HPV4v doses still appear in the 2026–2027 procurement cycles, the approval of a parliamentary budget amendment to enable the transition without delay.

THE WEIGHT IN NUMBERS

I yield, at the end, to the need to provide some auditable data — drawn from national records — on the gravest outcomes borne by Brazilians infected with HPV at some point in their lives. These are numbers that measure what is at stake. In 2021, the age-standardized cervical cancer mortality rate in Brazil's North region reached 9.07 deaths per 100,000 women — the leading cause of cancer death among women in that region.⁽¹¹⁾ In the Northeast (5.61/100,000) and Central-West (4.60/100,000), cervical cancer ranked third. More women die of this disease in Brazil's poorer regions — a disparity that vaccination can directly correct.

In 2024, DATASUS-SIM data recorded approximately 7,500 cervical cancer deaths in Brazil — 20.5 per day.⁽¹²⁾ Penile cancer, also HPV-associated, affects Brazil disproportionately: incidence ranges from 2.9 to 6.8 per 100,000 inhabitants, reaching 6.8/100,000 in the North region.⁽¹³⁾ About 486 penile amputations are performed in the country each year.⁽¹⁴⁾ A survey by the Brazilian Society of Urology, published in *O Globo* in February 2026, documented, between 2021 and 2025, more than 2,900 amputations (an average of 580 per year) and 2,359 deaths attributable to penile cancer (an average of 472 per year).⁽¹⁵⁾ These are not abstract statistics. They are preventable lives and mutilations.

IN CLOSING

The idea of writing such a letter, which can be understood as a manifesto, didn't just fall from the sky. If that's the case, great. But let it be a manifesto in continuous construction. Because this one didn't begin to be written now.

Thirteen years of HPV vaccination in Brazil represent real progress. The Vaccine March, the incorporation of HPV4v into the SUS, and the gradual broadening of eligibility are milestones that deserve recognition. But the current framework leaves identifiable high-risk populations unprotected — by arbitrary age limits and an outdated vaccine formulation. The scientific case for broadening eligibility and transitioning to HPV9v is robust. The ethical case is compelling. The financial argument favors action. What's lacking is the political will to decide now.

Table 1. HPV Vaccination Schedules in Brazil – April 2026

GROUP / INDICATION	SCHEDULE
Girls and Boys aged 9–14 years (Routine)	Single dose (month 0)
Girls and Boys aged 15–19 years (Catch-up vaccination) Through the 1st semester of 2026	Single dose (month 0)
Immunocompromised individuals aged 9–45 years (HIV, cancer, transplant recipients, PrEP users)	Three doses (months 0, 2, 6)
Recurrent Respiratory Papillomatosis (RRP) From 2 years of age	Three doses (months 0, 2, 6)
CIN 2, CIN 3, or AIS – High-Grade Cervical Lesions Women – no upper age limit (Initiate within 12 months after treatment)	Three doses (months 0, 2, 6)
Sexual violence victims ≥ 15 years	Three doses (months 0, 2, 6) Follow schedule according to age

Source: Figure 1 text transcribed by the author for the English version.

This commitment to health education — about HPV and about all sexually transmitted infections, once called venereal diseases — has always extended beyond clinical and academic settings. In 1998, HPV was the first topic discussed in an important television interview. — on the nationally broadcast program of Jô Soares.^(16,17) Our book *HPV Que Bicho É Esse?* reached eight editions between 2003 and 2011, with more than 50,000 copies distributed free of charge to the public and to health and education professionals.⁽¹⁸⁾ The short film *Programa da Larah*, adapted from the book, generated more than 30,000 DVDs distributed at events across Brazil and remains available on YouTube.⁽¹⁹⁾ In 2026, our CineDebate project continues to bring HPV education to public schools in Niterói.⁽²⁰⁾

SUPPLEMENTARY FIGURES




Figure 2. The Vaccine Revolt. View of Praça da República on November 14, 1904. Marian da Silva. Phot.-Ouvidor 91.⁽¹⁾

Conflict of interest

None to declare.

Ethics committee approval

Not applicable for this type of manuscript.

Grants or other funding

None to declare.

Use of AI in manuscript preparation

None to declare.



Figure 3. Demonstrators on Copacabana Beach, Rio de Janeiro, on May 19, 2013, calling for access to HPV vaccination through the SUS.




Figure 4. Flyer promoting the Vaccine March, Copacabana Beach, Rio de Janeiro. Author's personal collection.



Mauro Romero Leal Passos

Doctor, Associate Professor and Head of the STD Department, Fluminense Federal University



THE HPV VACCINE MARCH, RIO DE JANEIRO 2013

Copy for personal use only - distribution prohibited.

Rio de Janeiro, and indeed Brazil as a whole, is currently experiencing a serious STI epidemic (syphilis, congenital syphilis, chlamydia, HPV). As vaccines against HPV have been available since 2006, politicians in Rio de Janeiro have recently proposed a specific law making HPV vaccination compulsory. Press agencies, the scientific community and the general population are fully supportive of this bill. However, the government did not approve the HPV vaccine. As such, we held a Pro-Vaccine March, on May 19, on the sidewalk of Copacabana beach. This was a peaceful demonstration that aimed to convince the government of the urgent need to offer HPV vaccination for adolescents of both sexes. After the march we distributed educational materials such as a DVD of the short film: *Larah's Show*, "HPV What's That Bug?", available in YouTube.

Two weeks later, Brazil was brought to a halt by a huge wave of popular demonstrations with varying demands, ranging from better public transport to better conditions for education and health.

One month after the Pro-Vaccine March, the Federal Government announced that it will launch a comprehensive HPV information



campaign and begin to administer HPV vaccine to girls aged 10 and 11 years early in 2014. The aim of this program is to achieve a coverage of 80%, for a total of 3.3 million girls. On this occasion, doctors left their comfort zone and went out onto the streets to fight for one of the basic tenets of public health, namely disease prevention.

Some people claim that the Pro-Vaccine March may have been one of the triggers that sparked the subsequent wider ranging demonstrations of dissatisfaction with Brazilian public administrations as this was something that had never occurred before in Brazil: a popular demonstration demanding a specific vaccine.



Figure 1: Health professionals and the general population, including many children, taking part in the Pro-Vaccine March on Copacabana Beach, Rio de Janeiro (19 May 2013).



No 30-31 / p. 26
www.hpvtoday.com

Source: Author's personal collection.

Figure 5. Publication in HPV Today News, nos. 30–31, p. 26; 2013. Author's personal collection.

Role of the funding/sponsoring entity

Not applicable, as there was no funding.

Keywords

Vaccine; Vaccination; HPV; Human papillomavirus; Public health; Brazil.

REFERENCES

1. Instituto Butantan. Há mais de 100 anos, Revolta da Vacina foi marcada por mortes, estado de sítio e fake news. Instituto Butantan News. 05/11/2021. Available at: <https://butantan.gov.br/noticias/ha-mais-de-100-anos-revolta-da-vacina-foi-marcada-por-mortes-estado-de-sitio-e-fake-news> [Accessed May 19, 2026].
2. Marcha da Vacina defende campanha de vacinação contra HPV. História, Ciência, Saúde-Manguinhos – Fundação Oswaldo Cruz (Fiocruz). May 2013. Available at: <https://revistahscm.coc.fiocruz.br/marcha-da-vacina-defende-campanha-de-vacinacao-contra-hpv/> [Accessed May 19, 2026].
3. Em marcha em Copacabana, manifestantes pedem vacinação contra o HPV. Correio Braziliense. 19/05/2013. Available at: <https://www.correiobraziliense.com.br/app/noticia/brasil/2013/05/19/interna-brasil,366802/em-marcha-em-copacabana-manifestantes-pedem-vacinacao-contra-o-hpv.shtml> [Accessed May 19, 2026].
4. Ricardo Boechat entrevista Mauro Romero Leal Passos sobre o HPV – Marcha da Vacina. Rádio Band News FM Fluminense; May 28, 2013. Available at: <https://www.youtube.com/watch?v=9pqq-3ldqfg> [Accessed May 19, 2026].
5. Passos MRL. The HPV Vaccine March, Rio de Janeiro 2013. HPV Today News. 2013;(30–31):26.
6. Vermelho. No RJ, manifestantes pedem vacinação contra HPV. 19/05/2013. Available at: <https://vermelho.org.br/2013/05/19/no-rj-manifestantes-pedem-vacinacao-contra-hpv/> [Accessed May 19, 2026].
7. Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria nº 54, de 18 de novembro de 2013. Incorporação da vacina quadrivalente contra HPV na prevenção do câncer de colo do útero no SUS. Available at: https://bvsms.saude.gov.br/bvs/saudelegis/scie/2013/prt0054_18_11_2013.html [Accessed May 19, 2026].
8. HPVsemtabu. Esquemas vacinais do HPV – atualizado 2024–2026 [Instagram post]. Apr 19, 2026. Available at: <https://www.instagram.com/hpvsemtabu/> [Accessed May 19, 2026].
9. Beltrame A, Giuliano AR, Villa LL, et al. Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: a cross-sectional study. J Infect. 2026;92:106751.
10. Gomes SMS, Souza PCA, Rodrigues CF, Almeida YVO, Moura MA, Miranda A, et al. Association between HIV infection and oncogenic HPV subtypes in cisgender women. DST J bras Doenças Sex Transm. Available at: <https://www.bjstd.org/revista/article/view/1457/1542> [Accessed May 22, 2026].
11. Instituto Nacional de Câncer (INCA). Dados e números sobre câncer do colo do útero: relatório anual 2023. Rio de Janeiro: INCA; 2023. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/dados_e_numeros_colo_22marco2023.pdf [Accessed May 19, 2026].
12. Observatório da Saúde Pública. Mortes por câncer do colo do útero crescem 13,4% em três anos no Brasil. 11/03/2026. Available at: <https://medicinas.com.br/mortes-cancer-colo-uterio/> [Accessed May 19, 2026].
13. Fosse Júnior AM, Passos MRL, Schul A, Ribeiro DC, Ribeiro JGA, Bozzi R, et al. Impact of partial penectomy and glansctomy on couples' sexual function. Int Braz J Urol. 2025;51(5):e20250166.
14. Ministério da Saúde. Câncer de pênis: nota técnica traz orientações para profissionais de saúde e gestores. Mar 2024. Available at: <https://www.gov.br/saude/pt-br/assuntos/noticias/2024/marco/cancer-de-penis-nota-tecnica-traz-orientacoes-para-profissionais-de-saude-e-gestores> [Accessed May 19, 2026].
15. Sociedade Brasileira de Urologia. Câncer de pênis causou mais de 2,9 mil amputações nos últimos 5 anos. O Globo. 04/02/2026. Available at: <https://oglobo.globo.com/saude/noticia/2026/02/04/cancer-de-penis-causou-mais-de-29-mil-amputacoes-nos-ultimos-5-anos-revela-novo-estudo.ghtml> [Accessed May 19, 2026].
16. Soares J, Passos MRL. Entrevista – Programa Jô Soares 11:30, SBT, São Paulo, Dec 17, 1998. Part 1. Available at: <https://www.youtube.com/watch?v=JxwIq-6jqSk> [Accessed May 19, 2026].
17. Soares J, Passos MRL. Entrevista – Programa Jô Soares 11:30, SBT, São Paulo, Dec 17, 1998. Part 2. Available at: <https://www.youtube.com/watch?v=pG4Q3bAea4Y&t=10s> [Accessed May 19, 2026].
18. Passos MRL. HPV Que Bicho É Esse? 8th ed. Pirai: RQV Editora; 2011.
19. Passos MRL, Ottoni N, Carvalho T. Programa da Larah – HPV Que Bicho é Esse? [short film]. Instituto de Artes e Comunicação Social, Universidade Federal Fluminense; Niterói, 2011. Available at: <https://www.youtube.com/watch?v=t-GB7HkT6Fc> [Accessed May 19, 2026].
20. Passos MRL, Nery G. CineDebate sobre HPV seguido de roda de conversa. Colégio Estadual Guilherme Briggs (Brasil-Espanha), Santa Rosa, Niterói, RJ; May 15, 2026. Available at: <https://www.instagram.com/p/DYX7FGkpbIz/> [Accessed May 24, 2026].

Corresponding Author

MAURO ROMERO LEAL PASSOS

STD Sector (Department of Microbiology and Parasitology, Biomedical Institute), Universidade Federal Fluminense.
Outeiro São João Batista S/N, Campus do Valonguinho, Centro,
Niterói, RJ, Brazil. Postal code: 24210-150
E-mail: mauroromero@id.uff.br

Received: June 6, 2026

Accepted: July 12, 2026

